June 24, 2020 / 5:13 AM / 14 days ago

BRIEF-Orphazyme Updates On Phase 2 Study Of Arimoclomol In Gaucher Disease

June 24 (Reuters) - Orphazyme A/S:

* ORPHAZYME A/S - PHASE 2 STUDY OF ARIMOCLOMOL IN GAUCHER DISEASE DEMONSTRATES MARKED IMPROVEMENTS IN KEY CLINICAL MARKERS

* ORPHAZYME A/S - DATA SUPPORTS ORPHAZYME’S INTENTION TO PROCEED WITH PIVOTAL STAGE CLINICAL DEVELOPMENT IN GAUCHER DISEASE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below